시장보고서
상품코드
1429893

세계의 경구 생물제제 및 바이오시밀러 시장 보고서(2024년)

Oral Biologics & Biosimilars Global Market Report 2024

발행일: | 리서치사: The Business Research Company | 페이지 정보: 영문 175 Pages | 배송안내 : 2-10일 (영업일 기준)

    
    
    


■ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
■ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

경구 생물제제 및 바이오시밀러 시장 규모는 향후 수년간 급격하게 성장할 것으로 예상되고 있습니다. 2028년에는 20.9%의 연간 복합 성장률(CAGR)로 16조 6,345억 9,000만 달러로 성장할 것으로 예상됩니다. 예측 기간 중 예상되는 성장은 경구 생물제제 개발에 초점을 맞춘 활발한 R&D 활동, 주사제보다 정제 선호, 건강에 해로운 생활습관, 기술 발전, 경구 생물제제와 관련된 사용 편의성 증가에 기인하는 것으로 보입니다. 의료 접근성, 생물학적 제제 상환, 바이오시밀러 증가, 만성질환의 확산. 예측 기간 중 주요 동향으로는 경구 생물제제 시장에 대한 투자 증가, 이 분야의 혁신 증가로 인한 생물학적 제제로의 전환, 마이크로니들 인젝터 기반 의약품의 개발 등이 있습니다.

경구 생물제제 및 바이오시밀러 시장의 성장은 관절염, 천식, 암과 같은 만성질환의 유병률 증가로 인해 촉진될 것으로 예상됩니다. 장시간 노동, 제한된 신체 활동, 부적절한 식습관 등 건강에 해로운 생활습관 요인이 만성질환 발병률 증가에 기여하고 있습니다. 생물학적 제제는 이러한 증상을 치료하는 데 중요한 역할을 하며, 면역 체계를 자극하여 암과 같은 질병을 퇴치하는 데 도움이 될 수 있습니다. 유엔에 따르면 2030년까지 전 세계 사망자의 70%가 만성질환으로 인해 사망할 것으로 예상되고 있습니다. 이러한 만성질환의 급증은 생물학적 제제 및 바이오시밀러 시장의 성장을 가속하는 중요한 요인으로 작용하고 있습니다.

경구 생물제제 및 바이오시밀러 시장의 성장은 의료비 증가에 의해 촉진될 것으로 예상됩니다. 금액으로 측정되는 의료비에는 특정 기간 중 의료 제품 및 서비스에 지출되는 총 자원이 포함됩니다. 의료비 지출의 영향은 경구 생물제제 및 바이오시밀러의 개발, 채택 및 접근성에 영향을 미칩니다. 예를 들어 Centers for Medicare & Medicaid Services는 국민의료비(NHE)의 평균 성장률이 평균 GDP 성장률을 초과하여 GDP 대비 의료비 지출의 비율이 증가할 것으로 예측했습니다. 만성질환의 높은 유병률과 함께 의료비 증가는 경구 생물제제 및 바이오시밀러 시장의 성장을 가속할 것으로 예상됩니다.

목차

제1장 주요 요약

제2장 시장의 특징

제3장 시장 동향과 전략

제4장 거시경제 시나리오

  • 고인플레이션이 시장에 미치는 영향
  • 우크라이나·러시아 전쟁이 시장에 미치는 영향
  • 시장에 대한 COVID-19의 영향

제5장 세계 시장 규모와 성장

  • 세계의 경구 생물제제 및 바이오시밀러 시장 촉진요인과 억제요인
    • 시장 촉진요인
    • 시장 억제요인
  • 세계의 경구 생물제제 및 바이오시밀러 시장 규모 실적과 성장, 2018-2023년
  • 세계의 경구 생물제제 및 바이오시밀러 시장 규모와 성장 예측, 2023-2028년, 2033년

제6장 시장 세분화

  • 세계의 경구 생물제제 및 바이오시밀러 시장, 치료법별 세분화, 실적과 예측, 2018-2023년, 2023-2028년, 2033년
  • 림프구 모듈레이터
  • 인터류킨 저해제
  • 종양괴사인자 알파 저해제
  • 면역 활력제
  • GPCR 모듈레이터
  • 기타
  • 세계의 경구 생물제제 및 바이오시밀러 시장, 질환별 세분화, 실적과 예측, 2018-2023년, 2023-2028년, 2033년
  • 당뇨병
  • 관절염과 크론병
  • 감염증
  • 기타 자가면역질환
  • 기타
  • 세계의 경구 생물제제 및 바이오시밀러 시장, 분자 유형별 세분화, 실적과 예측, 2018-2023년, 2023-2028년, 2033년
  • 백신
  • 단백질과 펩티드
  • 모노클로널 항체
  • 기타
  • 세계의 경구 생물제제 및 바이오시밀러 시장, 유통 채널별 세분화, 실적과 예측, 2018-2023년, 2023-2028년, 2033년
  • 병원 약국
  • 소매 약국
  • 온라인 약국

제7장 지역과 국가 분석

  • 세계의 경구 생물제제 및 바이오시밀러 시장, 지역별, 실적과 예측, 2018-2023년, 2023-2028년, 2033년
  • 세계의 경구 생물제제 및 바이오시밀러 시장, 국가별, 실적과 예측, 2018-2023년, 2023-2028년, 2033년

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 개요

  • 경구 생물제제 및 바이오시밀러 시장의 경쟁 구도
  • 경구 생물제제 및 바이오시밀러 시장의 기업 개요
    • Merck &Co. Inc.
    • GlaxoSmithKline
    • Novo Nordisk
    • ALK-Abello
    • Aimmune Therapeutics Inc.

제31장 기타 대기업과 혁신적 기업

  • VIVUS Inc
  • Materia Medica Holding
  • VECTOR-MEDICA
  • Henlius
  • Innovent Biologics
  • Bio-Thera
  • Hisun Pharma
  • 3SBio
  • Beijing ShuangLu Pharmaceuticals
  • Qilu Pharmaceutical
  • Shanghai Fosun Pharmaceuticals
  • Biocon
  • Dr.Reddy's
  • Mylan
  • Kyowa Hakko Kirin

제32장 경쟁 벤치마킹

제33장 경쟁 대시보드

제34장 주요 합병과 인수

제35장 향후 전망과 잠재성 분석

제36장 부록

KSA 24.03.15

Biologics represent pharmaceuticals derived from living cells through highly intricate technology, whereas biosimilars are designed to function similarly to biologics but are not exact replicas. Within the oral biologics and biosimilar market, these drugs are administered orally to specifically target conditions such as Alzheimer's, multiple sclerosis, HIV/AIDS, and other serious ailments, as well as to address chronic diseases such as diabetes, arthritis, and cancer.

The primary therapy categories for oral biologics and biosimilars encompass lymphocyte modulators, interleukin inhibitors, tumor necrosis factor-alpha inhibitors, immunostimulants, GPCR modulators, and others. Interleukin inhibitors serve as immunosuppressive medications that impede the function of interleukins. Various diseases treated include asthma, Crohn's disease, cancer, infectious disease, other autoimmune conditions, and more, employing molecular types such as vaccines, proteins and peptides, monoclonal antibodies, and other therapies. Distribution channels for these treatments include hospital pharmacies, retail pharmacies, and online pharmacies.

The oral biologics and biosimilars market research report is one of a series of new reports from The Business Research Company that provides oral biologics and biosimilars market statistics, including oral biologics and biosimilars industry global market size, regional shares, competitors with an oral biologics and biosimilars market share, detailed oral biologics and biosimilars market segments, market trends and opportunities, and any further data you may need to thrive in the oral biologics and biosimilars industry. This oral biologics and biosimilars market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The oral biologics & biosimilars market size has grown exponentially in recent years. It will grow from $6471.49 billion in 2023 to $7788.01 billion in 2024 at a compound annual growth rate (CAGR) of 20.3%. The expansion observed in the historical period can be attributed to heightened collaboration and partnerships among market players aimed at gaining enhanced insights, a growing demand for immunology, increased requirements for cost-effective manufacturing processes, a progressively aging population, government initiatives, and the capacity to command high prices.

The oral biologics & biosimilars market size is expected to see exponential growth in the next few years. It will grow to $16634.59 billion in 2028 at a compound annual growth rate (CAGR) of 20.9%. The anticipated growth in the forecast period can be attributed to robust research and development activities focused on the development of oral biologics, a preference for pills over injections, the adoption of unhealthy lifestyles, technological advances, the ease of use associated with oral biologics, increased healthcare access, reimbursement of biologics, the rise in biosimilars, and the escalating prevalence of chronic diseases. Key trends in the forecast period include increased investment in the oral biologics market, a shift toward biologics driven by increasing innovation in that field, and the development of microneedle injectors-based drugs.

The growth of the oral biologics and biosimilar market is expected to be driven by the increasing prevalence of chronic diseases such as arthritis, asthma, and cancer. Unhealthy lifestyle factors, including long working hours, limited physical activity, and poor dietary habits, contribute to the rising incidence of chronic diseases. Biologics play a crucial role in treating these conditions, stimulating the immune system to combat diseases such as cancer. According to the United Nations, it is anticipated that chronic diseases will account for 70% of global fatalities by 2030. This surge in chronic diseases is a significant factor propelling the expansion of the biologics and biosimilar market.

The growth of the oral biologics and biosimilars market is also expected to be fueled by the increasing healthcare expenditure. Healthcare expenditure, measured in monetary terms, encompasses the total resources spent on healthcare goods and services within a specific period. The implications of healthcare expenditure impact the development, adoption, and accessibility of oral biologics and biosimilars. For instance, the Centers for Medicare & Medicaid Services project that the average National Health Expenditures (NHE) growth will exceed the average GDP growth, resulting in a rise in health spending as a share of GDP. The increasing healthcare expenditure, coupled with the high prevalence of chronic diseases, is expected to drive the growth of the oral biologics and biosimilars market.

A notable trend in the oral biologics and biosimilar market is the creation of new insulin biosimilars. Key industry players are investing in the development of biosimilar versions of insulin to capture market share. In November 2021, Biocon, an India-based biopharmaceutical company, launched interchangeable biosimilar insulin designed to control high blood sugar in patients with diabetes. These biosimilars are interchangeable with the reference brand, Lantus, allowing for substitution at the pharmacy counter. This trend reflects the strategic focus of companies in the market to capitalize on the growing demand for insulin biosimilars.

The role of technology is anticipated to continue driving market growth, particularly in the area of physiology simulation modeling. Advancements in this field contribute to greater efficiencies, such as Eli Lilly and Pfizer utilizing Amazon's Elastic Compute Cloud (EC2) platform for simulation models in early drug discovery. This approach significantly reduces the time required for simulations compared to traditional methods. The adoption of technology, especially in physiological simulation modeling, is expected to play a pivotal role in the further development of the oral biologics and biosimilar market.

In September 2023, Biocon Limited, an Indian pharmaceutical company, completed the acquisition of Eywa Pharma Inc. for $7.7 million. This strategic acquisition enhances Biocon's manufacturing infrastructure, ensuring a continuous supply and providing capacities for oral solid dosage products ahead of schedule. Eywa Pharma, Inc., a US-based pharmaceutical company specializing in oral biologics and biosimilars, aligns with Biocon's commitment to diversify and strengthen its market position.

Major companies operating in the oral biologics & biosimilars market report are Merck & Co. Inc., GlaxoSmithKline, Novo Nordisk, ALK-Abello, Aimmune Therapeutics Inc., VIVUS Inc., Materia Medica Holding, VECTOR-MEDICA, Henlius, Innovent Biologics, Bio-Thera, Hisun Pharma, 3SBio, Beijing ShuangLu Pharmaceuticals, Qilu Pharmaceutical, Shanghai Fosun Pharmaceuticals, Biocon, Dr.Reddy's, Mylan, Kyowa Hakko Kirin, Takeda, Mitsubishi Tanabe, AGC Biologics, BiosanaPharma, AstraZeneca, Bayer, Merck, Boehringer Ingelheim, Sanofi, Microgen, Geropharm, Valenta, NovaMedica, SynBio, Roche, Rani Therapeutics, Eli Lilly and Company, Emisphere Technologies Inc., Enteris BioPharma, Allena Pharmaceuticals, Abbvie, Johnson & Johnson, Pfizer Inc., Biogen Inc., Ache, Eurofarma, Teva Pharmaceuticals, Oramed Pharmaceuticals, Entera Bio, Julphar, Hikma Pharmaceuticals, Altis Biologics, Cipla Medpro South Africa, Genzyme

North America was the largest region in the oral biologics and biosimilar drugs market in 2023. The Middle East is expected to be the fastest-growing region in the forecast period. The regions covered in the oral biologics & biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the oral biologics & biosimilars market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The oral biologics and biosimilar market consists of sales of receptor modulators, biological agents, and biosimilar lymphocytes. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Oral Biologics & Biosimilars Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on oral biologics & biosimilars market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for oral biologics & biosimilars? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The oral biologics & biosimilars market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

  • 1) By Therapy: Lymphocyte Modulators; Interleukin Inhibitors; Tumor Necrosis Factor-Alpha Inhibitors; Immunostimulants; GPCR Modulators; Other Therapies
  • 2) By Disease: Diabetes; Arthritis and Crohn's Disease; Cancer; Infectious Disease; Other Autoimmune Disease; Other Diseases
  • 3) By Molecule Type: Vaccines; Proteins and Peptides; Monoclonal Antibodies; Other Molecule Types
  • 4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
  • Companies Mentioned: Merck & Co. Inc.; GlaxoSmithKline; Novo Nordisk; ALK-Abello; Aimmune Therapeutics Inc.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Oral Biologics & Biosimilars Market Characteristics

3. Oral Biologics & Biosimilars Market Trends And Strategies

4. Oral Biologics & Biosimilars Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On The Market
  • 4.2. Ukraine-Russia War Impact On The Market
  • 4.3. COVID-19 Impact On The Market

5. Global Oral Biologics & Biosimilars Market Size and Growth

  • 5.1. Global Oral Biologics & Biosimilars Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Oral Biologics & Biosimilars Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Oral Biologics & Biosimilars Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Oral Biologics & Biosimilars Market Segmentation

  • 6.1. Global Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Lymphocyte Modulators
  • Interleukin Inhibitors
  • Tumor Necrosis Factor-Alpha Inhibitors
  • Immunostimulants
  • GPCR Modulators
  • Other Tharpies
  • 6.2. Global Oral Biologics & Biosimilars Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Diabetes
  • Arthritis and Crohn's Disease
  • Cancer
  • Infectious Disease
  • Other Autoimmune Disease
  • Other Diseases
  • 6.3. Global Oral Biologics & Biosimilars Market, Segmentation By Molecule Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Vaccines
  • Proteins and Peptides
  • Monoclonal Antibodies
  • Other Molecule Types
  • 6.4. Global Oral Biologics & Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

7. Oral Biologics & Biosimilars Market Regional And Country Analysis

  • 7.1. Global Oral Biologics & Biosimilars Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Oral Biologics & Biosimilars Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Oral Biologics & Biosimilars Market

  • 8.1. Asia-Pacific Oral Biologics & Biosimilars Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Oral Biologics & Biosimilars Market, Segmentation By Molecule Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Oral Biologics & Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Oral Biologics & Biosimilars Market

  • 9.1. China Oral Biologics & Biosimilars Market Overview
  • 9.2. China Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Oral Biologics & Biosimilars Market, Segmentation By Molecule Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Oral Biologics & Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Oral Biologics & Biosimilars Market

  • 10.1. India Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Oral Biologics & Biosimilars Market, Segmentation By Molecule Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Oral Biologics & Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Oral Biologics & Biosimilars Market

  • 11.1. Japan Oral Biologics & Biosimilars Market Overview
  • 11.2. Japan Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Oral Biologics & Biosimilars Market, Segmentation By Molecule Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Oral Biologics & Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Oral Biologics & Biosimilars Market

  • 12.1. Australia Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Oral Biologics & Biosimilars Market, Segmentation By Molecule Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Oral Biologics & Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Oral Biologics & Biosimilars Market

  • 13.1. Indonesia Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Oral Biologics & Biosimilars Market, Segmentation By Molecule Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Oral Biologics & Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Oral Biologics & Biosimilars Market

  • 14.1. South Korea Oral Biologics & Biosimilars Market Overview
  • 14.2. South Korea Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Oral Biologics & Biosimilars Market, Segmentation By Molecule Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Oral Biologics & Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Oral Biologics & Biosimilars Market

  • 15.1. Western Europe Oral Biologics & Biosimilars Market Overview
  • 15.2. Western Europe Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Oral Biologics & Biosimilars Market, Segmentation By Molecule Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Oral Biologics & Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Oral Biologics & Biosimilars Market

  • 16.1. UK Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Oral Biologics & Biosimilars Market, Segmentation By Molecule Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Oral Biologics & Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Oral Biologics & Biosimilars Market

  • 17.1. Germany Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Oral Biologics & Biosimilars Market, Segmentation By Molecule Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Oral Biologics & Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Oral Biologics & Biosimilars Market

  • 18.1. France Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Oral Biologics & Biosimilars Market, Segmentation By Molecule Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France Oral Biologics & Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Oral Biologics & Biosimilars Market

  • 19.1. Italy Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Oral Biologics & Biosimilars Market, Segmentation By Molecule Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy Oral Biologics & Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Oral Biologics & Biosimilars Market

  • 20.1. Spain Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Oral Biologics & Biosimilars Market, Segmentation By Molecule Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain Oral Biologics & Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Oral Biologics & Biosimilars Market

  • 21.1. Eastern Europe Oral Biologics & Biosimilars Market Overview
  • 21.2. Eastern Europe Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Oral Biologics & Biosimilars Market, Segmentation By Molecule Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Oral Biologics & Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Oral Biologics & Biosimilars Market

  • 22.1. Russia Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Oral Biologics & Biosimilars Market, Segmentation By Molecule Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Oral Biologics & Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Oral Biologics & Biosimilars Market

  • 23.1. North America Oral Biologics & Biosimilars Market Overview
  • 23.2. North America Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Oral Biologics & Biosimilars Market, Segmentation By Molecule Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Oral Biologics & Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Oral Biologics & Biosimilars Market

  • 24.1. USA Oral Biologics & Biosimilars Market Overview
  • 24.2. USA Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Oral Biologics & Biosimilars Market, Segmentation By Molecule Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Oral Biologics & Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Oral Biologics & Biosimilars Market

  • 25.1. Canada Oral Biologics & Biosimilars Market Overview
  • 25.2. Canada Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Oral Biologics & Biosimilars Market, Segmentation By Molecule Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Oral Biologics & Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Oral Biologics & Biosimilars Market

  • 26.1. South America Oral Biologics & Biosimilars Market Overview
  • 26.2. South America Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Oral Biologics & Biosimilars Market, Segmentation By Molecule Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Oral Biologics & Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Oral Biologics & Biosimilars Market

  • 27.1. Brazil Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Oral Biologics & Biosimilars Market, Segmentation By Molecule Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Oral Biologics & Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Oral Biologics & Biosimilars Market

  • 28.1. Middle East Oral Biologics & Biosimilars Market Overview
  • 28.2. Middle East Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Oral Biologics & Biosimilars Market, Segmentation By Molecule Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Oral Biologics & Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Oral Biologics & Biosimilars Market

  • 29.1. Africa Oral Biologics & Biosimilars Market Overview
  • 29.2. Africa Oral Biologics & Biosimilars Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Oral Biologics & Biosimilars Market, Segmentation By Molecule Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Oral Biologics & Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Oral Biologics & Biosimilars Market Competitive Landscape And Company Profiles

  • 30.1. Oral Biologics & Biosimilars Market Competitive Landscape
  • 30.2. Oral Biologics & Biosimilars Market Company Profiles
    • 30.2.1. Merck & Co. Inc.
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. GlaxoSmithKline
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. Novo Nordisk
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. ALK-Abello
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. Aimmune Therapeutics Inc.
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Oral Biologics & Biosimilars Market Other Major And Innovative Companies

  • 31.1. VIVUS Inc
  • 31.2. Materia Medica Holding
  • 31.3. VECTOR-MEDICA
  • 31.4. Henlius
  • 31.5. Innovent Biologics
  • 31.6. Bio-Thera
  • 31.7. Hisun Pharma
  • 31.8. 3SBio
  • 31.9. Beijing ShuangLu Pharmaceuticals
  • 31.10. Qilu Pharmaceutical
  • 31.11. Shanghai Fosun Pharmaceuticals
  • 31.12. Biocon
  • 31.13. Dr.Reddy's
  • 31.14. Mylan
  • 31.15. Kyowa Hakko Kirin

32. Global Oral Biologics & Biosimilars Market Competitive Benchmarking

33. Global Oral Biologics & Biosimilars Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Oral Biologics & Biosimilars Market

35. Oral Biologics & Biosimilars Market Future Outlook and Potential Analysis

  • 35.1 Oral Biologics & Biosimilars Market In 2028 - Countries Offering Most New Opportunities
  • 35.2 Oral Biologics & Biosimilars Market In 2028 - Segments Offering Most New Opportunities
  • 35.3 Oral Biologics & Biosimilars Market In 2028 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제